Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Otamixaban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 20/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 18/20 | 1.00 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 1.00 |
| ▸ | F2 | P00734 | 5/20 | 0.81 |
| ▸ | PLG | P00747 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Otamixaban SCHEMBL29426323 | 1.00 | F10 (1.00) | F10PRSS1TMPRSS2F2PLG | |
| Otamixaban SCHEMBL52983 | 1.00 | F10 (1.00) | F10PRSS1TMPRSS2F2PLG | |
| Otamixaban SCHEMBL12589586 | 1.00 | F10 (1.00) | F10PRSS1TMPRSS2F2PLG | |
| Otamixaban SCHEMBL16588897 | 0.99 | F10 (0.98) | F10PRSS1TMPRSS2F2PLG | |
| Otamixaban SCHEMBL7890763 | 0.99 | F10 (0.98) | F10PRSS1TMPRSS2F2PLG | |
| SCHEMBL12805269 | 0.93 | F10 (0.86) | F10PRSS1TMPRSS2F2PLG | |
| SCHEMBL15489295 | 0.92 | F10 (1.00) | F10PRSS1TMPRSS2F2PLG | |
| SCHEMBL14542917 | 0.92 | F10 (0.86) | F10PRSS1TMPRSS2F2PLG | |
| SCHEMBL13160832 | 0.92 | F10 (1.00) | F10PRSS1TMPRSS2F2PLG | |
| SCHEMBL19222680 | 0.92 | F10 (0.86) | F10PRSS1TMPRSS2F2PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9993464-B2 | Otamixaban formulations with improved stability | SANOFI (FR) | 2018-06-12 | — | — | US | disclosed |
| US-9993464-B2 | Otamixaban formulations with improved stability | SANOFI (FR) | 2018-06-12 | — | — | US | disclosed |
| US-20170224668-A1 | OTAMIXABAN FORMULATIONS WITH IMPROVED STABILITY | SANOFI (FR) | 2017-08-10 | — | — | US | disclosed |
| US-20170224668-A1 | OTAMIXABAN FORMULATIONS WITH IMPROVED STABILITY | SANOFI (FR) | 2017-08-10 | — | — | US | disclosed |
| US-9597322-B2 | Otamixaban for use in the treatment of non-ST elevation acute coronary syndrome in patients planned to undergo coronary artery bypass grafting | SANOFI (FR) | 2017-03-21 | — | — | US | disclosed |
| US-9492437-B2 | Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients | SANOFI (FR) | 2016-11-15 | — | — | US | disclosed |
| US-20150202190-A1 | Otamixaban for Use in the Treatment of Non-ST Elevation Acute Coronary Syndrome in Patients Planned to Undergo Coronary Artery Bypass Grafting | SANOFI (FR) | 2015-07-23 | — | — | US | disclosed |
| US-8993602-B2 | Benzoic acid salt of otamixaban | SANOFI (FR) | 2015-03-31 | — | — | US | disclosed |
| US-20140024684-A1 | BENZOIC ACID SALT OF OTAMIXABAN | SANOFI (FR) | 2014-01-23 | — | — | US | disclosed |
| US-20140018398-A1 | OTAMIXABAN FORMULATIONS WITH IMPROVED STABILITY | SANOFI (FR) | 2014-01-16 | — | — | US | disclosed |
| US-20120252852-A1 | OTAMIXABAN FORMULATIONS WITH IMPROVED STABILITY | SANOFI (FR) | 2012-10-04 | — | — | US | disclosed |
| US-20120252852-A1 | OTAMIXABAN FORMULATIONS WITH IMPROVED STABILITY | SANOFI (FR) | 2012-10-04 | — | — | US | disclosed |
| US-20120238605-A1 | OTAMIXABAN FOR TREATMENT OF ELDERLY AND RENAL IMPAIRED NON-ST ELEVATION MYOCARDIAL INFARCTION PATIENTS | SANOFI (FR) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252852-A1 | OTAMIXABAN FORMULATIONS WITH IMPROVED STABILITY | F12, F11, PROC | F10 6/4885PRSS1 932/4885TMPRSS2 1191/4885 |
| US-20140018398-A1 | OTAMIXABAN FORMULATIONS WITH IMPROVED STABILITY | F12, F11, PROC | F10 4/4885PRSS1 939/4885TMPRSS2 1210/4885 |
| US-20170224668-A1 | OTAMIXABAN FORMULATIONS WITH IMPROVED STABILITY | F12, F11, PROC | F10 4/4885PRSS1 939/4885TMPRSS2 1210/4885 |
| US-20140024684-A1 | BENZOIC ACID SALT OF OTAMIXABAN | F11, VKORC1, F10 | F10 3/4885PRSS1 655/4885TMPRSS2 793/4885 |
| US-20150202190-A1 | Otamixaban for Use in the Treatment of Non-ST Elevation Acute Coronary Syndrome in Patients Planned to Undergo Coronary Artery Bypass Grafting | TNNI3, PCSK9, TNNT2 | F10 22/4885PRSS1 194/4885TMPRSS2 195/4885 |
| US-20120238605-A1 | OTAMIXABAN FOR TREATMENT OF ELDERLY AND RENAL IMPAIRED NON-ST ELEVATION MYOCARDIAL INFARCTION PATIENTS | TNNI3, MB, ABAT | F10 460/4885PRSS1 2617/4885TMPRSS2 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.